- CEO
- Yi Xiong Shi
- Full Time Employees
- 2,886
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1, Amber Road Zhangzhou FU China 363000
- IPO Date
- Jun 16, 2003
- Business
- Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436.SS) manufactures and sells traditional Chinese medicines under the Pien Tze Huang brand, along with related healthcare products; its core offerings include flagship Pien Tze Huang tablets and capsules for clearing heat, removing toxins, and treating abscesses, boils, and traumatic injuries, as well as Angong Niuhuang Pills, Yindan Pinggan Capsules, Liuwei Dihuang Pills, Chuangbei Qingfei Syrup, Xinshubao Tablets, Heat-clearing and cough-relieving granules, Huoxiang Zhengqi water and capsules, and Bezoar detoxification tablets; the company also produces health foods, beverages, cosmetics, daily chemical products, Chinese herbal decoction pieces, medical equipment, and tonics targeting liver diseases, respiratory conditions, cardiovascular issues, colds, and dermatology.
Founded in 1956 through the restructuring of Zhangzhou Pharmaceutical Factory and listed on the Shanghai Stock Exchange in 2003, the company maintains headquarters in Zhangzhou, Fujian province, China, and operates primarily in the domestic market with exports to over 30 countries including Singapore, Thailand, Malaysia, Canada, Brazil, and Argentina.
Zhangzhou Pientzehuang functions as a subsidiary of Zhangzhou Jiulongjiang Group Co Ltd and supports multiple R&D platforms such as a National Enterprise Technology Center and provincial engineering centers; it serves pharmaceutical retail, hospitals, and international markets through 34 holding subsidiaries, eight joint-stock companies, and four industry funds.
Recent developments include a February 2024 cooperation agreement with Beijing Tong Ren Tang Group to promote traditional Chinese medicine globally; accelerated expansion of Zhangzhou Pientzehuang Chinese Patent Medicine outlets with over 30 new sites in Q1 2025 and plans for 600 more nationwide; a 200 million yuan investment in the Gaoxin Runxin Healthcare Industry Investment Partnership in 2025 targeting pharmaceuticals, medical devices, and synthetic biology; new product launches such as health-preserving beverages and skin-rejuvenating cosmetics for younger consumers; clinical trials for PZH2108 in liver cancer and PZH2111 for FGFR abnormalities; and selection as one of China's brands favored by foreigners in 2024.